XML 99 R37.htm IDEA: XBRL DOCUMENT v3.24.2.u1
LICENSE AND DISTRIBUTION AGREEMENTS (Details)
1 Months Ended 3 Months Ended 6 Months Ended 12 Months Ended
Mar. 31, 2024
USD ($)
Jun. 30, 2024
USD ($)
Jun. 30, 2023
USD ($)
Mar. 31, 2023
USD ($)
Mar. 31, 2022
USD ($)
Jun. 30, 2024
USD ($)
Jun. 30, 2024
EUR (€)
Jun. 30, 2023
USD ($)
Dec. 31, 2022
USD ($)
Dec. 31, 2023
USD ($)
Jan. 24, 2022
USD ($)
LICENSE AGREEMENTS                      
Revenue   $ 3,971,438 $ 3,917,467     $ 8,878,315   $ 6,904,163      
Deferred revenue, current   15,392,151       15,392,151       $ 24,270,465  
Commercialization and Distribution Agreement with Nippon Shinyaku Co, Limited, United States                      
LICENSE AGREEMENTS                      
Potential milestone payments   90,000,000.0       90,000,000.0          
Milestone payments to be made upon completion of certain phases   10,000,000.0       10,000,000.0          
Upfront payment         $ 30,000,000.0 30,000,000.0          
Deferred revenue liability   3,400,000       3,400,000         $ 40,000,000.0
Revenue   4,000,000.0 $ 3,900,000     8,900,000   $ 6,900,000      
Deferred revenue, current   $ 3,400,000       $ 3,400,000          
Commercialization and Distribution Agreement with Nippon Shinyaku Co, Limited, United States | Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2024-07-01                      
LICENSE AGREEMENTS                      
Revenue, remaining performance obligation, expected timing of satisfaction, period   12 months       12 months          
Revenue, Remaining Performance Obligation, Percentage   100.00%       100.00%          
Commercialization and Distribution Agreement with Nippon Shinyaku Co, Limited, Japan                      
LICENSE AGREEMENTS                      
Potential milestone payments       $ 89,000,000.0              
Milestone payments to be made upon completion of certain phases   $ 10,000,000.0       $ 10,000,000.0          
Upfront payment       $ 12,000,000.0              
Deferred revenue liability   12,000,000.0       12,000,000.0          
Deferred revenue, current   12,000,000.0       12,000,000.0          
CSMC | Commercialization and Distribution Agreement with Nippon Shinyaku Co, Limited, United States                      
LICENSE AGREEMENTS                      
Deferred revenue liability   40,000,000.0       $ 40,000,000.0          
Rome License Agreement                      
LICENSE AGREEMENTS                      
Notice period           90 days 90 days        
JHU License Agreement                      
LICENSE AGREEMENTS                      
Notice period           60 days 60 days        
Threshold period to cure breach           30 days 30 days        
CSMC License Agreement                      
LICENSE AGREEMENTS                      
Notice period           90 days 90 days        
Exosomes License Agreement                      
LICENSE AGREEMENTS                      
Notice period           90 days 90 days        
Minimum | Commercialization and Distribution Agreement with Nippon Shinyaku Co, Limited, United States                      
LICENSE AGREEMENTS                      
Share of product revenue (in percent)                     30.00%
Minimum | Rome License Agreement                      
LICENSE AGREEMENTS                      
Minimum annual royalty payments | €             € 20,000        
Maximum | Commercialization and Distribution Agreement with Nippon Shinyaku Co, Limited, United States                      
LICENSE AGREEMENTS                      
Potential milestone payments                     $ 605,000,000.0
Share of product revenue (in percent)                     50.00%
Maximum | JHU License Agreement                      
LICENSE AGREEMENTS                      
Potential milestone payments   $ 1,850,000       $ 1,850,000          
Completion Of Phase Two Due | JHU License Agreement                      
LICENSE AGREEMENTS                      
Milestones paid                 $ 250,000    
Milestone payments to be made upon completion of certain phases                 $ 500,000    
Patent rights | JHU License Agreement                      
LICENSE AGREEMENTS                      
Agreement effective period           20 years 20 years        
Non Payment of Royalties | CSMC License Agreement                      
LICENSE AGREEMENTS                      
Agreement termination period           30 days 30 days        
Non Payment of Royalties | Exosomes License Agreement                      
LICENSE AGREEMENTS                      
Threshold period to cure breach           30 days 30 days        
CSMC Agreement Compliance | CSMC License Agreement                      
LICENSE AGREEMENTS                      
Agreement termination period           90 days 90 days        
CSMC Agreement Compliance | Exosomes License Agreement                      
LICENSE AGREEMENTS                      
Threshold period to cure breach           90 days 90 days        
Material Breach Has Not Been Cured | CSMC License Agreement                      
LICENSE AGREEMENTS                      
Agreement termination period           90 days 90 days        
Material Breach Has Not Been Cured | Exosomes License Agreement                      
LICENSE AGREEMENTS                      
Threshold period to cure breach           90 days 90 days        
Fails To Cure Breach after Notice From CSMC | CSMC License Agreement                      
LICENSE AGREEMENTS                      
Agreement termination period           90 days 90 days        
Fails To Cure Breach after Notice From CSMC | Exosomes License Agreement                      
LICENSE AGREEMENTS                      
Threshold period to cure breach           90 days 90 days        
Overdue payment obligation | CSMC License Agreement | CSMC                      
LICENSE AGREEMENTS                      
Revenue $ 10,000,000.0                    
Milestone payments, percentage claimed by CSMS   10.00%       10.00%          
Milestone payments, amount claimed by CSMS $ 1,000,000.0